{"nctId":"NCT00772603","briefTitle":"Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures","startDateStruct":{"date":"2008-11"},"conditions":["Epilepsies, Partial"],"count":366,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"2400 mg SPN-804","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 2400mg SPN-804"]},{"label":"1200mg SPN-804","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 1200mg SPN-804"]}],"interventions":[{"name":"Placebo","otherNames":["sham treatment"]},{"name":"2400mg SPN-804","otherNames":["Oxcarbazepine extended-release","Oxtellar XR","Oxtellar"]},{"name":"1200mg SPN-804","otherNames":["Oxcarbazepine extended-release","Oxtellar XR","Oxtellar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Capable of complying with the study procedures.\n* Able to provide written informed consent\n* Male or female aged 18 to 65 years, inclusive.\n* Diagnosis of partial onset seizures\n* Minimum of three seizures per 28 days\n* Receiving treatment with 1-3 AEDs\n* Refractory to at least one AED\n* No progressive neurological conditions by recent MRI/CT\n* Adequate birth control in women of child-bearing potential\n\nExclusion Criteria:\n\n* Refractory to OXC for reasons of efficacy\n* Recent status epilepticus\n* Recent non-epileptic seizures\n* Current diagnosis of major depression\n* Recent suicidal plan or intent or more than one attempt\n* Current use of oxcarbazepine, felbamate for \\< 18 months, phenytoin with levels \\>15mcg/mL or frequent need for rescue benzodiazepines\n* Current use of sodium-lowering non-seizure medications.\n* Clinically significant hepatic, renal, or cardiovascular function\n* History of recent substance abuse\n* Females who are pregnant or lactating.\n* Hypersensitivity to OXC or related drugs\n* Difficulty swallowing study medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PCH(T), ITT","description":"Percent change (PCH) in seizure frequency per 28d relative to Baseline, Treatment Phase (PCH\\[T\\]), Intent-to-Treat population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.90","spread":"53.11"},{"groupId":"OG001","value":"-38.20","spread":"69.84"},{"groupId":"OG002","value":"-28.70","spread":"67.34"}]}]}]},{"type":"SECONDARY","title":"PCH(M)- ITT","description":"Percent change in seizure frequency per 28 days relative to Baseline, Maintenance Period (PCH\\[M\\]), Intent-to-Treat population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.15","spread":null},{"groupId":"OG001","value":"-35.30","spread":null},{"groupId":"OG002","value":"-32.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder Rate, ITT","description":"Percent of patients with a positive response, defined as a 50% or greater reduction in seizure frequency per 28 days relative to Baseline, Treatment Phase, Intent-to-Treat population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Seizure-Free Rates, ITT","description":"Percent of patients seizure-free during Treatment Phase, Intent-to-Treat population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Seizure Free Rate, ITT, (M)","description":"Percent of patients seizure-free during Maintenance, Intent-to-Treat population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":123},"commonTop":["Dizziness","Somnolence","Headache","Vomiting","Diplopia"]}}}